Opioid agonist and antagonist bivalent ligands as receptor probes

P. S. Portoghese, G. Ronsisvalle, D. L. Larson, C. B. Yim, L. M. Sayre, A. E. Takemori

Research output: Contribution to journalArticlepeer-review

74 Scopus citations

Abstract

Bivalent ligands are molecules which contain two pharmacophores linked by a connecting chain (spanner). The present report describes the use of oxymorphamine (Oxy) and naltrexamine (Nal) as the opioid agonist and antagonist pharmacophores separated by a variable length spanner composed of succinyl-bis-oligoglycine. The agonist series, [CH2CO(Gly)nOxy]2, and antagonist series, [CH2CO(Gly)nNal]2, were synthesized (n = 0-4) and tested on the electrically stimulated GPI. All of the antagonist bivalent ligands (Nal) antagonized the effects of morphine, with the greatest potency enhancement (60 x) residing with the succinyl (n = 0) congener. A dramatically different SAR profile was observed in the agonist (Oxy) series where the greatest potency enhancement (17 x) occurs when n = 2. By contrast with the antagonist series the agonist bivalent ligand with n = 0 is equipotent to its monovalent agonist analogue. The significance of these results with respect to the possibility of discrete opioid agonist and antagonist recognition sites are discussed.

Original languageEnglish (US)
Pages (from-to)1283-1286
Number of pages4
JournalLife Sciences
Volume31
Issue number12-13
DOIs
StatePublished - Sep 1982

Fingerprint

Dive into the research topics of 'Opioid agonist and antagonist bivalent ligands as receptor probes'. Together they form a unique fingerprint.

Cite this